CompletedPhase 3

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

United States459 participantsStarted 2007-07

Plain-language summary

To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject has completed the treatment period of a previous blinded study of pimavanserin * The subject is willing and able to provide consent * Caregiver is willing and able to accompany the subject to all visits Exclusion Criteria: * Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder * Subject is judged by the Investigator to be inappropriate for the study

What they're measuring

Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)

Timeframe: From first to last study drug dose plus 30 days

Trial details

NCT IDNCT00550238

SponsorACADIA Pharmaceuticals Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-05-30

Results submitted2019-05-29

View on ClinicalTrials.gov More Parkinson's Disease Psychosis trials